Fixed drug eruption: a prototypic disorder mediated by effector memory T cells
Supplied as a lyophilized powder with batch testing and laboratory verification
Medicinal Ingredients
1 HNMR (300 MHz, DMSO- d 6 , ppm): H 11.49 (s, 1H, hydrazine-N H ), 9.74 (s, 1H, 3-hydroxy-4-methoxybenzylidene-N=C H ), 9.35 (s, 1H, O H ), 8.30 (s, 1H, 4-hydroxy-3-methoxy benzohydrazide-O H ), 7.49 (s, 1H, 4-hydroxy-3-methoxy benzohydrazide-C 2 H ), 7.45 (d, J = 6.0 Hz, 1H, 4-hydroxy-3-methoxy benzohydrazide-C 6 H ), 7.28 (s, 1H, 3-hydroxy-4-methoxybenzylidene-C 2 H ), 7.05 (d, J = 6.0 Hz, 1H, 4-hydroxy-3-methoxy benzohydrazide-C 5 H ), 6.97 (d, J = 6.0 Hz, 1H, 3-hydroxy-4-methoxybenzylidene-C 6 H ), 6.88 (d, J = 6.0 Hz, 1H, 3-hydroxy-4-methoxybenzylidene-C 5 H ), 3.85 (brs, 3H, 3-hydroxy-4-methoxybenzylidene-OC H 3 ), 3.81 (brs, 3H, 4-hydroxy-3-methoxy benzohydrazide-OC H 3 )
This synthetically-produced peptide was initially created to treat a variety of conditions